New gout drug faces off against standard treatment in major trial
NCT ID NCT07414394
First seen Mar 01, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This study tests a new gout drug, tigulixostat, against an existing one, febuxostat, in 600 Chinese adults with gout. The goal is to see which better lowers uric acid levels below a target threshold over 24 weeks, while also monitoring safety, gout attacks, and quality of life for up to a year. Participants must be 18 or older, have a gout diagnosis, and meet specific uric acid levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Fudan University HuaShan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200040, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.